This site is intended for Healthcare professionals only.
×

Lupin launches Minocycline Hydrochloride extended release tablets in US


Lupin launches Minocycline Hydrochloride extended release tablets in US

The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said.

Mumbai: Drug major, Lupin has recently launched Minocycline Hydrochloride extended-release tablets in the US market. Minocycline Hydrochloride is used to treat inflammatory lesions of acne. However, the tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

The company has launched Minocycline Hydrochloride extended-release tablets USP in the strength of 55 mg, after receiving approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said.

Also Read: Lupin gets USFDA nod to Methylprednisolone tablets to treat inflammation

As per IQVIA MAT December 2018 data, the product had annual sales of around $76.8 million in the US, Lupin said.

The product is a generic version of Medicis Pharmaceutical Corporation’s Solodyn tablets in the same strength, it added.
The tablets are indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older, it added.
Lupin was founded in 1968 by Desh Bandhu Gupta, then an Associate Professor at BITS-Pilani, Rajasthan. Gupta died on 26 June 2017 and was replaced as chairman by his wife, Manju Deshbandhu Gupta.

The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.



Source: with inputs
0 comment(s) on Lupin launches Minocycline Hydrochloride extended release tablets in US

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted